Richard /Ca/ Murray - Apr 4, 2023 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role
Director
Signature
/s/ Caroline G. Gammill, by power of attorney
Stock symbol
JNCE
Transactions as of
Apr 4, 2023
Transactions value $
-$72,572
Form type
4
Date filed
4/6/2023, 04:37 PM
Previous filing
Jan 11, 2023
Next filing
May 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Sale -$72.6K -39.2K -17.2% $1.85 189K Apr 4, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The automatic sale instructions for the sell-to-cover were intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended, and to be interpreted to comply with the requirements of Rule 10b5-1(c), and these instructions were given on September 17, 2019.